Literature DB >> 22387050

Imatinib resistance due to a novel tri-nucleotide insertion in the SH2/C lobe interface of BCR/ABL kinase domain between position K357 and N358.

Shantashri Vaidya, Archana Sonawani, Susan Idicula-Thomas, Babu Rao Vundinti, Kanjaksha Ghosh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22387050     DOI： 10.1016/j.leukres.2012.02.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.

Authors:  Sandra C Dos Santos; Nuno P Mira; Ana S Moreira; Isabel Sá-Correia
Journal:  OMICS       Date:  2012-07-09

2.  Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.

Authors:  Shantashri Vaidya; Babu Rao Vundinti; Chandrakala Shanmukhaiah; Prantar Chakrabarti; Kanjaksha Ghosh
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

3.  Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy.

Authors:  Peter Keating; Alberto Cambrosio; Nicole C Nelson; Andrei Mogoutov; Jean-Philippe Cointet
Journal:  Front Pharmacol       Date:  2013-05-07       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.